Skip to main content
. Author manuscript; available in PMC: 2014 Jun 11.
Published in final edited form as: Anticancer Agents Med Chem. 2013 May;13(4):595–602. doi: 10.2174/1871520611313040009

Figure 9. Effect of in vivo administration of INT2-31 plus gemcitabine in a direct fresh biopsy xenograft model of pancreatic cancer.

Figure 9

Daily IP administration of low dose INT2-31 (20 mg/kg) in combination with gemcitabine (25mg/kg every 3 days) chemotherapy decreased growth of a direct pancreatic cancer xenograft compared to any therapy alone. (* p<0.05 for combination treatment)